MOBI

AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report second quarter 2026 financial results on Tuesday, August 11, 2026. Mobia Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.

Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years

AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to maintain CPT® Code 64568, the procedure code used for the Vivistim® procedure, under the New Technology Ambulatory Payment Classification (APC) 1580 for calendar year (CY) 2027, with an associated hospital outpatient payment rate of approximately $45,000, unchanged from the CY 2026 rate. CMS is expected to publish the final Hospital Outpatient Prospective Payment System (OPPS) rule in November of this year, with any changes taking effect January 1, 2027.

Mobia Medical (NASDAQ:MOBI) was initiated with a ‘Buy' rating and a $16 price target by Bank of America, which cited the company's growth potential in stroke recovery treatment and a large addressable market for its Vivistim system. Mobia's Vivistim therapy combines rehabilitation exercises with a vagus nerve stimulation (VNS) device designed to help chronic stroke survivors improve upper-limb function.